Zimmer Biomet Holdings Inc
ZBH
ISIN US98956P1021 / Valor 1262932
Zimmer Biomet Holdings Inc
UMushroom community rating:
About company
Zimmer Biomet Holdings Inc is a global leader in musculoskeletal healthcare, providing a comprehensive range of products and services to help healthcare professionals treat patients suffering from joint disorders and other orthopedic conditions. The company offers a wide variety of innovative solutions, including joint replacement implants, surgical tools, and biologics, to improve patient outcomes and enhance quality of life. With a strong focus on research and development, Zimmer Biomet is dedicated to advancing the field of orthopedics and delivering cutting-edge technologies to meet the evolving needs of healthcare providers and patients worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Net Sales Growth
Zimmer Biomet Holdings Inc. reported net sales of $1.942 billion for the second quarter of 2024, reflecting a 3.9% increase over the same period in the previous year. On a constant currency basis, the net sales growth was 5.6%, indicating strong performance despite currency fluctuations.
Earnings Per Share
For the second quarter of 2024, Zimmer Biomet Holdings Inc. reported diluted earnings per share (EPS) of $1.18. On an adjusted basis, the diluted EPS was $2.01, showcasing the company's ability to generate significant earnings after accounting for certain adjustments.
Net Earnings
Zimmer Biomet Holdings Inc. achieved net earnings of $242.8 million in the second quarter of 2024. On an adjusted basis, net earnings were $415.0 million, highlighting the company's profitability after making necessary adjustments.
Revenue Guidance Update
Zimmer Biomet Holdings Inc. updated its full-year 2024 financial guidance, adjusting the expected impact of foreign currency exchange. The company reaffirmed its constant currency revenue growth and adjusted EPS guidance, projecting a reported revenue change of 4.0% to 5.0% and adjusted diluted EPS between $8.00 and $8.15.
Geographic Sales Performance
In the second quarter of 2024, Zimmer Biomet Holdings Inc. reported net sales of $1.106 billion in the United States and $835.8 million internationally. This represents a 3.5% increase in the U.S. and an 8.5% increase internationally on a constant currency basis, demonstrating robust growth across different regions.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
22300 M
Market cap (USD)
369,762
Daily traded volume (Shares)
107.1 / 105.25
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
